RespireRx Pharmaceuticals — Cortex Pharmaceuticals — Rodman and Renshaw 16th Annual Global Investment Conference (September 2014)
33 slides from RespireRx Pharmaceuticals's conference presentation, Sep 5, 2014

Slide 1: Cortex Pharmaceuticals, Inc. at Rodman and Renshaw Conference
i PHARMACEUTICALS, INC. Cortex Pharmaceuticals, Inc. Rodman and Renshaw 16th Annual Global Investment Conference September 10, 2014

Slide 2: Forward-looking statements
The matters discussed in this presentation that are not historical facts are "forward-looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," "anticipates," "intends," "expects," "projects" and words of similar import. Readers are

Slide 3: Cortex is the leader in innovative pharmaceuticals for breathing disorders
Cortex is the leader in the discovery and development of innovative pharmaceuticals for the treatment of breathing disorders » Drug-induced respiratory depression (RD) - ampakines ° Acute use — surgical anesthesia with propofol ° Semi-acute use — post-surgical pain management with opiates ° Chronic

Slide 4: Cortex Drug Platforms
Cortex Drug Platforms Ampakines ¢ Positive allosteric modulators of AMPA glutamate receptors * Positive effects for treatment of central sleep apnea in Phase 2A study ¢ Positive effects for treatment of drug-induced respiratory depression in Phase 2A study Cannabinoids ¢ Dronabinol (D9-THC) is a gen

Slide 5: AMPA Receptors Mediate Synaptic Transmission in the Brain
AMPA Receptors Mediate Synaptic Transmission in the Brain » Glutamate is the major excitatory neurotransmitter in the CNS » Fast excitatory transmission is mediated by AMPA-type glutamate receptors » Ampakines are positive, allosteric modulators of the AMPA-type glutamate receptor » Prolong and stre

Slide 6: Cortex's AMPAKINE Technology
Cortex’s AMPAKINE Technology Low and High Impact Platforms Low Impact AMPAKINES ¢ Stimulate one pathway « Enhance synaptic transmission « Reverse RD * No convulsant activity * CX717, CX1739, CX1942, CX1763 / AMPA Receptor High Impact AMPAKINES * Stimulate both pathways « Enhance synaptic transmissio

Slide 7: AMPAKINES — Novel Treatment for Respiratory Depression
AMPAKINES — Novel Treatment for Respiratory Depression PreBétzinger : PreBétzinger Complex output Complex « Neurons in this brainstem region control inspiratory breathing rhythm * PreBotC neurons use AMPA receptors for signaling Initial research conducted by Dr. J. Greer, U. Alberta ° Opiates and ot

Slide 8: Respiratory Failure: A Very Serious Hospital Safety Problem
Respiratory Failure: A Very Serious Hospital Safety Problem HealthGrades Patient Safety in American Hospitals Study 2010 - 28 Appendix E: Patient Safety Events and Attributable Mortality and Excess Charge Appendix E: Patient Safety Events and Their Attributable Mortality and Excess Charge Among Medi

Slide 9: CX1739: An Oral Phase Ampakine
CX1739: An Oral Phase 2 Ampakine » Stage of Development ° Completed Phase 1 in healthy volunteers and Phase 2a in central sleep apnea ° Ready for Phase 2 studies in opiate-induced respiratory depression and central sleep apnea » Targeted Indication ° Oral therapy for opiate- and propofol-induced res

Slide 10: Reversal of Opioid-induced Respiratory Depression with an Ampakine in Rats
Reversal of Opioid-induced Respiratory Depression with an Ampakine in Rats Fentanyl Prolonged opiate-induced respiratory depression leads to lethality CX17339 injection Fentanyl 10s CX1739 reverses opiate-induced respiratory depression and prevents lethality

Slide 11: Reversal of Propofol-induced RD with an Ampakine in the Rat
Reversal of Propofol-induced RD With an Ampakine in the Rat Experimental Design: — Administer a lethal dose of propofol to rats — Inject CX1739 within 1 minute Propofol TT Propofol + CX1739 LN * LLL 11

Slide 12: Two clinical studies in healthy volunteers with CX717
» Two Clinical studies were run in normal, healthy volunteers with CX717 an older generation Ampakine » Moderate respiratory depression was induced experimentally by infusion of the opioid, Alfentanil » Respiratory and analgesia end-points were measured

Slide 13: VVUIito VV sai IMAM INS VIVE
VVUIito VV sai IMAM INS VIVE i ee C—IPlacebo TL — 510X717 NORMAL---<--29-7 | ------- -- x = **P<0.01 RD <8 BPM---§--®+7 | r---= a NS - Not Significant 2 ao 4 0 v v Ly Baseline +Alfentanil +Naloxone Data are exp! d as the basal respi ry rate. N= 15 and 16 per group. CX717 dose is 1500mg.

Slide 14: CX717 Maintains the Analgesic Properties of Opioids
CX717 Maintains the Analgesic Properties of Opioids Analgesia 2.05 C—1Placebo > 159 mamcX717 2 7) 5 1.04 NS n c \v ‘wo Delivery of a electrical a 0.55 | | stimulation to finger 0.0 T v v Baseline +Alfentanil +Naloxone ¢ Alfentanil reduced the pain sensitivity (produced analgesia) ¢« Analgesia was un

Slide 15: Sleep Apnea: A Large Market Opportunity
Sleep Apnea: A Large Market Opportunity » Sleep Apnea ° Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10s during sleep ° Three types: Obstructive, Central & Mixed » The Sleep Apnea Market is Large ° 18 million U.S. adults with moderate or severe sleep apnea °

Slide 16: Central Sleep Apnea
Central Sleep Apnea » Characterized by a lack of drive from the brain to breathe during sleep — similar response as in treatment of RD » Manifestations of CSA ° Narcotic-induced central apnea (70% chronic users) ° Heart failure patients (up to 40%) ° Idiopathic CSA (5% sleep apnea patients) » Standa

Slide 17: Severity of CSA Correlated with Increased Mortality in HF Patients
The Severity of CSA is Correlated with Increased Mortality in HF Patients wu. 8 AHI less than S per hour oo AHI equal or greater than 5 per hour Reducing Central Sleep Apnea May Reduce Mortality in Heart Failure Patients Survival % eos 8 8 8 &$ B 8 8 8B 8B 0 0 DD #® 50 6 70 8 90 10 1 ~ WO MO BO KO 1

Slide 18: CX1739 Sleep Apnea Clinical Study Design
CX1739 Sleep Apnea Clinical Study Design Design Randomized, double-blind, placebo-controlled study Population 20 adults with moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject receives either placebo or a single dose of 900mg CX1739 one hour before lights out Prima

Slide 19: Apnea-Hypopnea Scores (Responders)
Apnea-Hypopnea Scores (Responders) Apnea-Hypopnea Index CX1739 3/15 \An Placebo 0/4 Apnea-Hypopnea Time CX1739 5/15 Cau Placebo 0/4 Why do some patients respond, and others not ? * Aresponder has at least a 40% decrease in the respective parameter

Slide 20: CX1739 Was More Effective on Mixed and Central Sleep Apneas
CX1739 Was More Effective on Mixed and Central Sleep Apneas Obstructive Apneas Mixed Apneas Central Apnea 35 6 12 30 5 10 S22 hie sc To ocd te 8 £4 20 £3 £3 ot o o3 wc 6 ® © 15. © od oo c> c> c> ow am 2 am 4 ZU 10. gu gu 1 2 0 0 =) iN y a x v oD * * & * ~~ & 2 2 2 2

Slide 21: CX1942: A Soluble Ampakine
CX1942: A Soluble Ampakine » Mechanism of Action ° Low Impact Positive Allosteric Modulator of AMPA receptors ° Water-soluble for injectable dosage forms » Stage of Development ° Injectable routes being studied in animal models of respiratory depression ° Supported by SBIR contract » Targeted Indica

Slide 22: Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA) » Obstructive sleep apnea (OSA) involves a decrease or complete halt in airflow despite an ongoing effort to breathe during sleep ° Occurs when the muscles relax during sleep ° Soft tissue in back of throat collapses and obstructs upper airway » Affects 18 MM adults in

Slide 23: Obstructive Sleep Apnea: Scope of the Problem in the US
Obstructive Sleep Apnea Scope of the Problem in the US Estimated Annual Annual Indicated Disease State US Estimated Cost Drug Therapy Prevalence to Society Expenditures OSA™S 18.0 MM $75.0 Billion $0 Asthma®7 16.4 MM $18.3 Billion $13.5 Billion Hypertension®"° 43.2 MM $73.4 Billion $48.5 Billion Dia

Slide 24: CPAP limitations
Works as an air splint to keep upper airway open during sleep 30% of patients prescribed CPAP never initiate treatment when prescribed a machine Over 50% of patients stop using CPAP in the first year of use ; may only wear 3-4h/night

Slide 25: Obstructive Sleep Apnea
Obstructive Sleep Apnea | nent that can significantly improve OSA and reduce excessive daytime sleepiness (EDS)

Slide 26: Dronabinol for Treatment of OSA
Dronabinol for Treatment of OSA: A Phase 2 Compound » Mechanism of Action ° Dronabinol is (D-9)THC, a cannabinoid agonist » Stage of Development ° Schedule III drug available by prescription, low risk of addiction e Approved for the treatment of anorexia in AIDS patients and nausea and vomiting in c

Slide 27: Dronabinol Phase 2A Clinical Study in OSA
Dronabinol Phase 2A Clinical Study in OSA » Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA » Randomized to Placebo (N=5) or Dronabinol (N=17) for 21 days ° 2.5, 5 and 10 mg/night studied with weekly dose escalation » Overnight polysomnogram (PSG) at baseli

Slide 28: Dronabinol Reduced the AHI in OSA Subjects
Dronabinol Reduced the AHI in OSA Subjects AHI Mean % Change from Baseline to End of Treatment 40% P=0.17 Dronabinol Placebo Reduction in Sleep Apnea 8 e 28

Slide 29: Apnea Suppression as a Function of Dose and Time
Apnea Suppression as a Function of Dose and Time -8 + uw 1st Half -12 5 = 2nd Half AAHI versus Baseline a ° \ n= 17 n= 13 n=8 The plasma half-life of dronabinol is 2 — 4 hours. 29

Slide 30: Dronabinol Phase 2B Trial in OSA
Dronabinol Phase 2B Trial in COA o Phase 2 study re-initiated January, 2014 ° Top line data by 4Q2015 ° 120 subjects (40/group, 6 wks dosing) ° Doses: Placebo, 2.5 mg, 10 mg qd o Study costs funded by NIH Grant for $5 MM > a

Slide 31: Protecting Dronabinol in the Marketplace
Protecting Dronabinol in the Marketplace » Issued Method-of-Use patent for dronabinol and OSA e Expires in 2025 » Proprietary dosage and pulse-dose formulation to provide efficacy over entire night ° Pending patent applications » Off-label use of generics and medical marijuana are not covered by thi

Slide 32: Respiratory Disorders
Respiratory Disorders Depression (injectable) Indication Compound piscony | eltical | a | Obstructive Sleep Apnea Dronabinol — Central Sleep Apnea in CHF | CX1739 > Drug-induced Respiratory Depression (oral) €x1739 Drug-induced Respiratory | A945 ———y 32

Slide 33: Key Objectives for the Next Months
Key Objectives for the Next 16 Months Compound Indication Status Estimated Estimated Start Date Completion Dronabino Obstructive Sleep I Apnea Opiate-induced RD Phase IIA 1Q2015 3Q2015 Phase IIB started 4Q2015 CX1739 ; Propofol-induced RD Phase IIA 2Q2015 4Q2015 Pre- CX1942 Injectable for RD clinica
Source: SEC EDGAR · 8-K filed Sep 5, 2014
More decks from RespireRx Pharmaceuticals Inc
Investor Summit, November 14-15, 202232 slides · Nov 10, 2022
Investor Presentation (November 2022)38 slides · Nov 7, 2022
Investor Presentation (September 2022)23 slides · Sep 13, 2022
Biotech Showcase 202213 slides · Dec 14, 2021
Investor Presentation (December 2021)15 slides · Dec 14, 2021
Investor Presentation (May 2021)18 slides · May 6, 2021